Faropenem: review of a new oral penem
- 1 April 2007
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 5 (2) , 185-198
Abstract
Faropenem medoxomil is a new orally administered penem antibiotic. Its chiral tetrahydrofuran substituent at position C2 is responsible for its improved chemical stability and reduced CNS effects, compared with imipenem. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many Gram-positive and -negative aerobes and anaerobes, and is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. However, faropenem is not active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, Pseudomonas aeruginosa or Stenotrophomonas maltophilia. Prospective, multicenter, randomized, double-blind, comparative (not vs placebo) clinical trials of acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) and uncomplicated skin and skin structure infections (uSSSIs) have demonstrated that faropenem medoxomil has equivalent efficacy and safety compared with cefuroxime, clarithromycin, azithromycin, amoxicillin, cefpodoxime and amoxicillin-clavulanate. The evidence supports faropenem medoxomil as a promising new oral beta-lactam with proven efficacy and safety for the treatment of a variety of community-acquired infections. However, the US FDA recently rejected faropenem for all four indications stating that the clinical trials in ABS and AECB should have been performed versus a placebo. In the CAP studies, the FDA stated that they could not be certain of the validity of the study population actually having the disease and for uSSSI, the FDA stated that only a single trial was not adequate evidence of efficacy for this indication.Keywords
This publication has 33 references indexed in Scilit:
- Redefining penemsBiochemical Pharmacology, 2006
- In Vitro Evaluation of Faropenem Activity Against Anaerobic BacteriaJournal of Chemotherapy, 2005
- Chemical and Microbiologic Aspects of Penems, a Distinct Class of β‐Lactams: Focus on FaropenemPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2003
- Beta-Lactamase Stability of FaropenemChemotherapy, 2003
- Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from FranceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Target Affinities of Faropenem to and Its Impact on the Morphology of Gram-Positive and Gram-Negative BacteriaChemotherapy, 2003
- The Art of Fusion: From Penams and Cephems to PenemsChemotherapy, 2003
- Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae , Haemophilus influenzae , and Moraxella catarrhalisAntimicrobial Agents and Chemotherapy, 2002
- Pseudomonas aeruginosa Reveals High Intrinsic Resistance to Penem Antibiotics: Penem Resistance Mechanisms and Their InterplayAntimicrobial Agents and Chemotherapy, 2001
- Role of Penicillin-Binding Proteins in the Initiation of the AmpC β-Lactamase Expression in Enterobacter cloacaeAntimicrobial Agents and Chemotherapy, 2000